0001144204-15-070766.txt : 20151214 0001144204-15-070766.hdr.sgml : 20151214 20151214170518 ACCESSION NUMBER: 0001144204-15-070766 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151210 FILED AS OF DATE: 20151214 DATE AS OF CHANGE: 20151214 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC. CENTRAL INDEX KEY: 0001137883 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 207273918 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 UNIVERSITY PLAZA DRIVE STREET 2: SUITE 320 CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 201-488-0460 MAIL ADDRESS: STREET 1: 3 UNIVERSITY PLAZA DRIVE STREET 2: SUITE 320 CITY: HACKENSACK STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC DATE OF NAME CHANGE: 20041122 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC DATE OF NAME CHANGE: 20030827 FORMER COMPANY: FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC DATE OF NAME CHANGE: 20010409 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TAUB MALCOLM S CENTRAL INDEX KEY: 0001305117 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36641 FILM NUMBER: 151286601 MAIL ADDRESS: STREET 1: 1350 AVENUE OF THE AMERICAS CITY: NEW YORK STATE: NY ZIP: 10019 4 1 v426885_4.xml OWNERSHIP DOCUMENT X0306 4 2015-12-10 0 0001137883 BRAINSTORM CELL THERAPEUTICS INC. BCLI 0001305117 TAUB MALCOLM S 605 THIRD AVENUE 34TH FLOOR NEW YORK NY 10158 1 0 0 0 Common Stock 2015-12-10 4 S 0 12500 2.74 D 51388 D Common Stock 2015-12-11 4 S 0 980 2.66 D 50408 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.70 to $2.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.65 to $2.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ Thomas B. Rosedale (pursuant to power of attorney) 2015-12-14